General practitioners' and psychiatrists' attitudes towards antidepressant withdrawal.

Antidepressants public mental health public opinion withdrawal side-effects

Journal

BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931

Informations de publication

Date de publication:
18 Jun 2020
Historique:
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 20 6 2020
Statut: epublish

Résumé

There has been a recent rise in antidepressant prescriptions. After the episode for which it was prescribed, the patient should ideally be supported in withdrawing the medication. There is increasing evidence for withdrawal symptoms (sometimes called discontinuation symptoms) occurring on ceasing treatment, sometimes having severe or prolonged effects. To identify and compare current knowledge, attitudes and practices of general practitioners (GPs) and psychiatrists in Cornwall, UK, concerning antidepressant withdrawal symptoms. Questions about withdrawal symptoms and management were asked of GPs and psychiatrists in a multiple-choice cross-sectional study co-designed with a lived experience expert. Psychiatrists thought that withdrawal symptoms were more severe than GPs did (P = 0.003); 53% (22/42) of GPs and 69% (18/26) of psychiatrists thought that withdrawal symptoms typically last between 1 and 4 weeks, although there was a wide range of answers given; 35% (9/26) of psychiatrists but no GPs identified a pharmacist as someone they may use to help manage antidepressant withdrawal. About three-quarters of respondents claimed they usually or always informed patients of potential withdrawal symptoms when they started a patient on antidepressants, but patient surveys say only 1% are warned. Psychiatrists and GPs need to effectively warn patients of potential withdrawal effects. Community pharmacists might be useful in supporting GP-managed antidepressant withdrawal. The wide variation in responses to most questions posed to participants reflects the variation in results of research on the topic. This highlights a need for more reproducible studies to be carried out on antidepressant withdrawal, which could inform future guidelines.

Sections du résumé

BACKGROUND BACKGROUND
There has been a recent rise in antidepressant prescriptions. After the episode for which it was prescribed, the patient should ideally be supported in withdrawing the medication. There is increasing evidence for withdrawal symptoms (sometimes called discontinuation symptoms) occurring on ceasing treatment, sometimes having severe or prolonged effects.
AIMS OBJECTIVE
To identify and compare current knowledge, attitudes and practices of general practitioners (GPs) and psychiatrists in Cornwall, UK, concerning antidepressant withdrawal symptoms.
METHOD METHODS
Questions about withdrawal symptoms and management were asked of GPs and psychiatrists in a multiple-choice cross-sectional study co-designed with a lived experience expert.
RESULTS RESULTS
Psychiatrists thought that withdrawal symptoms were more severe than GPs did (P = 0.003); 53% (22/42) of GPs and 69% (18/26) of psychiatrists thought that withdrawal symptoms typically last between 1 and 4 weeks, although there was a wide range of answers given; 35% (9/26) of psychiatrists but no GPs identified a pharmacist as someone they may use to help manage antidepressant withdrawal. About three-quarters of respondents claimed they usually or always informed patients of potential withdrawal symptoms when they started a patient on antidepressants, but patient surveys say only 1% are warned.
CONCLUSIONS CONCLUSIONS
Psychiatrists and GPs need to effectively warn patients of potential withdrawal effects. Community pharmacists might be useful in supporting GP-managed antidepressant withdrawal. The wide variation in responses to most questions posed to participants reflects the variation in results of research on the topic. This highlights a need for more reproducible studies to be carried out on antidepressant withdrawal, which could inform future guidelines.

Identifiants

pubmed: 32552920
doi: 10.1192/bjo.2020.48
pii: S2056472420000484
pmc: PMC7345735
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e64

Références

Int J Clin Pharm. 2017 Aug;39(4):686-696
pubmed: 28653260
BMC Fam Pract. 2017 Jun 17;18(1):72
pubmed: 28623894
Fam Pract. 2014 Aug;31(4):419-26
pubmed: 24850795
Addict Behav. 2020 Mar;102:106157
pubmed: 31841871
BMJ. 2019 Mar 29;364:l1508
pubmed: 30926584
BMJ Open. 2019 Jul 4;9(7):e027837
pubmed: 31278099
Addict Behav. 2019 Oct;97:111-121
pubmed: 30292574
Curr Psychiatry Rep. 2018 Aug 28;20(10):86
pubmed: 30155583
BJGP Open. 2019 Oct 29;:
pubmed: 31662317
Am Fam Physician. 2006 Aug 1;74(3):449-56
pubmed: 16913164
Psychol Med. 2020 Jan;50(2):177-186
pubmed: 31779735
CNS Drugs. 2006;20(8):665-72
pubmed: 16863271
Psychother Psychosom. 2015 Feb 21;84(2):72-81
pubmed: 25721705
Ther Adv Psychopharmacol. 2015 Dec;5(6):357-68
pubmed: 26834969

Auteurs

Joanne McCabe (J)

University of Exeter Medical School Knowledge Spa, Royal Cornwall Hospital, Truro, UK.

Mike Wilcock (M)

Royal Cornwall Hospitals NHS Trust, Treliske, Truro, UK.

Kate Atkinson (K)

Cornwall Partnership NHS Foundation Trust, Truro, UK.

Richard Laugharne (R)

University of Exeter Medical School Knowledge Spa, Royal Cornwall Hospital, Truro; and Caradon CMHT, Trevillis House, Lodge Hill, Cornwall Partnership NHS Foundation Trust, Truro, UK.

Rohit Shankar (R)

University of Exeter Medical School Knowledge Spa, Royal Cornwall Hospital, Truro; and Adult ID, Neurodevelopmental services Truro, Cornwall Partnership NHS Foundation Trust, Truro, UK.

Classifications MeSH